AnaptysBio Recruits Dr. Gerrit Los to Lead Translational Biology

SAN DIEGO, April 6, 2015 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Gerrit Los, Ph.D. as Vice President of Pharmacology.   Dr. Los will lead translational biology across AnaptysBio's proprietary antibody pipeline, including programs focused upon novel immuno-oncology opportunities.  Dr. Los will report to Dr. Macro Londei, AnaptysBio's Chief Development Officer.

"We are thrilled to welcome Dr. Los to AnaptysBio's product development team and look forward to his contribution to the multiple antibody programs advancing to the clinic over the next 18 months," said Hamza Suria, President and Chief Executive Officer of AnaptysBio. "Progressing our pipeline assets through to clinical proof-of-concept is a strategic priority for AnaptysBio and Dr. Los' translational research depth will provide key support to our upcoming value inflection events.  By coupling this development team to our antibody generation platform, AnaptysBio is strongly positioned to continue building its pipeline of therapeutics across emerging inflammation and immuno-oncology applications."

Dr. Los joins AnaptysBio from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics.  Prior to Five Prime, Dr. Los was head of cancer biology at Pfizer, where he directed teams responsible for the development of several targeted cancer therapeutics, including crizotinib, axitinib and palbociclib.  Prior to Pfizer, Dr. Los was an Adjunct Professor at the University of California San Diego where his work focused on identifying response markers in cancer.  Dr. Los received his Ph.D. in Pharmacology from the Free University in Amsterdam, Netherlands and was a Dutch Cancer Society post-doctoral fellow at the Netherlands Cancer Institute.  Dr. Los has published more than 100 peer-reviewed papers and is recognized as a leading expert in immuno-oncology and pharmacology. 

About AnaptysBio

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio is developing a pipeline of therapeutic antibody candidates, including novel programs in immuno-oncology and inflammation.  AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  AnaptysBio has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, Momenta, DARPA, DTRA and TESARO.  For more information, visit www.anaptysbio.com.

Logo - http://photos.prnewswire.com/prnh/20111205/SF16052LOGO

SOURCE AnaptysBio, Inc.

Related Links

http://www.anaptysbio.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED